儿童期起病肥厚型心肌病的临床特征与结局
基于SHaRe注册队列7677例HCM患者,按诊断年龄分层为婴儿期、儿童期和成年期。儿童期起病HCM总体复合终点事件率约2%/年,肌节变异携带者占63%且预后更差,室性心律失常和晚期心衰治疗需求高于成年期起病者。
要点
- 儿童期起病HCM肌节变异携带率63%,携带者心衰风险增加2.39倍。
- 儿童期起病较成年期起病危及生命室性心律失常风险增加36%。
- 儿童期起病需移植或心室辅助装置的风险是成年期起病的1.99倍。
核心结论
- 儿童期起病HCM更常见肌节疾病,危及生命室性心律失常风险更高,晚期心衰治疗需求更大。
- 这些发现有助于理解疾病自然史并辅助临床风险分层。
研究设计与样本
- 观察性队列研究,纳入Sarcomeric Human Cardiomyopathy Registry(SHaRe)中7677例HCM患者。
- 按诊断年龄分层:<1岁为婴儿期(184例,2.4%),1-18岁为儿童期(1128例,14.7%),>18岁为成年期(6365例,82.9%)。
主要发现
- 儿童期起病HCM总体复合终点事件率约2%/年,基线访视后第一个十年内室性心律失常最常见,第二个十年末心衰和房颤更常见。
- 儿童期起病HCM中肌节变异占63%,携带者心衰风险增加[HRadj 2.39(1.36-4.20),P=0.003],总体复合结局风险增加67%[HRadj 1.67(1.16-2.41),P=0.006]。
- 与成年期起病HCM相比,儿童期起病发生危及生命室性心律失常风险增加36%[HRadj 1.36(1.03-1.80)],需移植或心室辅助装置风险增加1.99倍[HRadj 1.99(1.23-3.23)]。
临床怎么用
- 对儿童期起病HCM应重视肌节变异检测以辅助风险分层。
- 儿童期起病HCM需关注室性心律失常风险及晚期心衰治疗需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Childhood-onset hypertrophic cardiomyopathy (HCM) is far less common than adult-onset disease, thus natural history is not well characterized. We aim to describe the characteristics and outcomes of childhood-onset HCM. METHODS AND RESULTS: We performed an observational cohort study of 7677 HCM patients from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Hypertrophic cardiomyopathy patients were stratified by age at diagnosis [<1 year (infancy), 1-18 years (childhood), >18 years (adulthood)] and assessed for composite endpoints reflecting heart failure (HF), life-threatening ventricular arrhythmias, atrial fibrillation (AF), and an overall composite that also included stroke and death. Stratifying by age of diagnosis, 184 (2.4%) patients were diagnosed in infancy; 1128 (14.7%) in childhood; and 6365 (82.9%) in adulthood. Childhood-onset HCM patients had an ∼2%/year event rate for the overall composite endpoint, with ventricular arrhythmias representing the most common event in the 1st decade following baseline visit, but HF and AF becoming more common by the end of the 2nd decade. Sarcomeric variants were more common in childhood-onset HCM (63%) and carried a worse prognosis than non-sarcomeric disease, including a greater than two-fold increased risk of HF [HRadj 2.39 (1.36-4.20), P = 0.003] and 67% increased risk of the overall composite outcome [HRadj 1.67 (1.16-2.41), P = 0.006]. When compared with adult-onset HCM, childhood-onset was 36% more likely to develop life-threatening ventricular arrhythmias [HRadj 1.36 (1.03-1.80)] and twice as likely to require transplant or ventricular assist device [HRadj 1.99 (1.23-3.23)]. CONCLUSION: Patients with childhood-onset HCM are more likely to have sarcomeric disease, carry a higher risk of life-threatening ventricular arrythmias, and have greater need for advanced HF therapies. These findings provide insight into the natural history of disease and can help inform clinical risk stratification.
引用
- Marston NA, Han L, Olivotto I, et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J. 2021. PMID: 33769460. doi:10.1093/eurheartj/ehab148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。